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or previously published work. The algorithm has been subse-
quently further tested on a second cohort2 to assess the reproduc-
ibility of the approach.
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O-23 IMPRINTED GENE METHYLATION IN BLOOD AND RISK OF
BREAST CANCER
P. Haggarty, G. Hoad, P. Scott, L. Simpson, A. Samad, E. Smyth, S.D.
Heys. RINH, University of Aberdeen, Aberdeen, UK
Loss of imprinting is a common observation in tumours but it
is not known whether this results from other pathologies or
whether imprinting changes may predispose to disease. We set
out to determine whether women newly diagnosed with breast
cancer had altered imprinted gene methylation in non-tumour
tissue (blood cells) compared to women without the disease.
Over 1000 women – newly diagnosedwith breast cancer and dis-
ease free controls – were recruited at Aberdeen Breast Clinic. A
sample of 92 controls and 92 cases were matched for age, weight,
height, BMI and menopausal status. Multiple methylation sites
were measured in two imprinted genes (IGF2 and PEG3) in blood
DNA. Methylation was determined by pyrosequencing using a Qia-
gen PyroMark MD system after bisulphite conversion of DNA using
Epitect Bisulfite kits (Qiagen, Crawley, UK). Analysis of variancewas
carried out using STATA 11MP (Stata Corp, College Station, USA).
The mean population methylation level was 47.6 (SD 2.5)% for
PEG3 and 50.0 (SD 5.5)% for IGF2. Compared to controls, women
diagnosed with breast cancer had significantly different levels
of methylation in PEG3 (p < 0.001). IGF2 methylation was also dif-
ferent between groups but this was only approaching statistical
significance (p = 0.058). Methylation was not related to meno-
pausal status. These differences in normal tissue suggest that
altered imprinted gene methylation may precede the develop-
ment of the disease. They also point to early life programming
as a possible cause of breast cancer.
This study was funded by Breast Cancer Campaign (Project
2008MayPR46).
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O-24 INVESTIGATION OF BRCA1 AND BRCA2 UNCLASSIFIED
VARIANTS USING RNA STUDIES: EXPERIENCES AND INTEREST-
ING CASES FROM THE WEST MIDLANDS REGIONAL GENETICS
LABORATORY
Elizabeth Perrott, Pauline K. Rehal, Ana Maria Brasgoldberg,
Fiona Macdonald. West Midlands Regional Genetics Laboratory,
Birmingham, UK
A very successful high throughput screening strategy for the
BRCA1 and BRCA2 genes has now been established at the West
Midlands Regional Genetics laboratory (WMRGL) since 2006. How-
ever having resolved the problems of large backlogs and long
reporting times the challenge has now shifted to the prediction
of the functional consequence of variants of unknown clinical
significance which account for a significant proportion of
reported sequence alterations in BRCA1 and BRCA2.
Laboratory methods to identify which of these sequence vari-
ants are pathogenic mutations would have utility for counseling
and clinical decision making when identified in patients with a
family history of breast cancer.
The WMRGL currently undertakes RNA investigations on
unclassified sequence variants for several familial cancer disor-
ders for both local and external referrals. To date we have under-
taken analysis on 92 cases covering 13 different disorders
including non-cancers. RNA investigations specifically for BRCA1
or BRCA2 variants have been performed on 25 samples. An over-
view of the service will be presented together with results from
interesting cases highlighting the challenges faced in interpreta-
tion of this data.
doi:10.1016/j.ejcsup.2010.06.025
O-25 ER POSITIVE SCREEN DETECTED BREAST CANCERS (SDBC)
DO NOT REQUIRE CHEMOTHERAPY
N.J. Bundred a, J. Morris b, S. Cheung c, W.F. Knox d, G.M.
Lawrence c. aAcademic Department of Surgery, University Hospital of
South Manchester, UK. bAcademic Department of Statistics, University
Hospital of South Manchester, UK. cWest Midlands Cancer Intelligence
Unit, Birmingham, UK. dAcademic Department of Pathology, University
Hospital of South Manchester, UK
Meta-analysis of symptomatic breast cancer trials advises
chemotherapy to women <70 years of age at high risk of death
(i.e. benefit of >1% survival benefit from treatment) but UK screen
detected breast cancers (SDBC) (aged 50–65 years) have an overall
97.2% 5 year relative survival compared to 77.6% for symptomatic
cancers. Guidelines recommend chemotherapy for all cancers
>10 mm in size (i.e. 35% SDBC) whereas in 2001/2 only 23% SDBC
in the UK received chemotherapy.
To determine which women benefit from chemotherapy, we
analysed 1681 symptomatic and SDBC in Manchester. SDBC had
a lower risk of relapse with 5 year cancer mortality for oestro-
gen receptor (ER) positive cancers being low in the Excellent
(0%), Good (GPG) (1%) and Moderate Prognostic Group 1
(MPG1) (4%) but higher in the symptomatic GPG (4.1%) and
MPG1 (15.5%) (p 6 0.001). The ABS at BASO Audit 2001/2 indi-
cates 5 year survival improvements in the Moderate Prognostic
Group 2 (MPG2) and the Poor Prognostic Group (PPG) for SDBC
since 1990.
ER positive SDBC had a <0.6% mortality annually whereas the
symptomatic cancers had a 5% annual mortality in the first
5 years. ER positive SDBCs represent a group with a low risk of
relapse, not requiring chemotherapy. Improvements in survival
of SDBC relate to better treatment of ER negative and HER2
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positive breast cancers and have occurred predominantly in the
MPG2 and PPG.
doi:10.1016/j.ejcsup.2010.06.026
O-26 DOES THE ADDITIONAL PROGNOSTIC BENEFIT OF
SCREENING IN EARLY BREAST CANCER (EBC) APPLY TO ALL
PATIENTS?
J. Mansell, O. Olusegun, C.R. Wilson, W.J. Angerson, J.C. Doughty.
Western Infirmary, Glasgow, UK
Introduction: Screen detection may confer prognostic benefit
independent of disease stage in EBC leading to suggestions that
mode of presentation should be considered when deciding adju-
vant therapy. We aim to determine if this additional prognostic
benefit is seen in all patients.
Methods: Data from 3 centres in Glasgow of consecutive
women aged between 50 and 65 years with EBC diagnosed
between 1995 and 2001 were examined. Patients were grouped
by mode of presentation into screen detection and symptomatic.
Breast cancer specific survival was the end-point. Multivariate
analysis including interaction between mode of presentation
and pathology was performed with further subgroup analysis if
the interaction was significant.
Results: Women (1534) were included with a median follow-up
of 5.5 years. Mode of presentation was screening in 1007 (65.6%)
women. After adjustment for pathology screen detection had no
significant survival benefit: HR 0.73 (0.50–1.08, p = 0.116). Mode
of presentation had an independently significant interaction with
both nodal status and ER status (p = 0.003 and p = 0.01 respec-
tively). Further analysis demonstrated that screening was an
independent predictor of survival in the 1–3 node positive group
(HR 0.33 (0.15–0.73), p = 0.006); the ER positive group (HR 0.53
(0.31–0.89), p = 0.017) and in the moderate NPI group only (HR
0.54 (0.31–0.94), p = 0.030).
Conclusions: These results provide evidence of a significant
interaction between mode of presentation and pathology. Further
research is needed before incorporating mode of presentation
into decisions regarding adjuvant therapy.
doi:10.1016/j.ejcsup.2010.06.027
O-27 EPITHELIAL PROLIFERATION (Ki67) IS PROGNOSTIC IN
SYMPTOMATIC BUT NOT SCREEN DETECTED BREAST CANCERS
(SDBC)
N.J. Bundred a, W.F. Knox b, A. Cramer c,d, M. Wilson e, R. Prasad a,
J. Morris f. aAcademic Department of Surgery, University Hospital of
South Manchester, Manchester, UK. bAcademic Department of
Pathology, University Hospital of South Manchester, Manchester,
UK. cDepartment of Histopathology, Christie Hospital, Manchester,
UK. dDepartment of Cytogenetics, Christie Hospital, Manchester,
UK. eAcademic Department of Radiology, University Hospital of South
Manchester, Manchester, UK. fAcademic Department of Statistics,
University Hospital of South Manchester, Manchester, UK
Epithelial proliferation has been used to determine therapy in
the St. Gallen guidelines (Ki67 P30% indicates the need for che-
motherapy). UK screen detected breast cancers (SDBC) (aged 50–
65 years) have an overall 97.2% 5 year relative survival compared
to 77.6% for symptomatic cancers.
To determine the value of Ki67 in post-menopausal breast
cancer in women aged 50–65 years, we have studied Ki67 in
1270 women with either symptomatic cancers (n = 412) or SDBC
(n = 858). Mean Ki67 in SDBC was 21.4 (SD 10.3) and 34.2 (SD
16.2) in symptomatic cancers (p = 60.001). For each 10 unit
increase in Ki67, increases in distant relapse occurred (RR 1.43:
95%CI; 1.32–1.55). Twelve per cent of symptomatic and 2% of SDBC
had died within 5 years.
Out of 458 women with Ki67 620, 27 died within 10 years
(93.2% survival) compared to 143 out of 775 with Ki67 P20%
(79% survival) (p = 60.001).
Ki67 was prognostic for symptomatic cancers of distant
relapse (p = 0.01) and mortality (p = 0.01) but was only predic-
tive of recurrence (p = 0.01) and not mortality in SDBC. In
SDBC, Ki67 values in the 2% who died did not differ from
those alive at 5 years and use of cut-off score of Ki67 of
P20% would have potentially selected 35% of women for che-
motherapy and a Ki67 of P30% would have potentially
selected 12% of women.
Epithelial proliferation is prognostic, but not predictive, of
chemotherapy benefit in SDBC.
doi:10.1016/j.ejcsup.2010.06.028
O-28 FACTORS ASSOCIATEDWITH A COMPLETE PATHOLOGICAL
RESPONSE FOLLOWING NEO-ADJUVANT CHEMOTHERAPY FOR
BREAST CANCER
Angharad Pryce, Weehaan Pang, Adele Francis, Daniel Rea.
University Hospital, Birmingham, UK
Background: Chemotherapy for treatment of breast cancer
has been increasingly used in neo-adjuvant setting to facilitate
pre-operative reduction in tumour size to make amenable to
surgery or to facilitate breast-conserving surgery in the place
of mastectomy. A complete pathological response to chemo-
therapy is associated with a greater overall and disease free
survival.
Purpose: This study aimed to identify molecular markers,
disease and treatment factors associated with complete patho-
logical response to neo-adjuvant chemotherapy in breast
cancer.
Methods: Fifty-six patients who received neo-adjuvant chemo-
therapy at our institution between January 2006 and January 2010
with complete histological information and definitive surgery at
the time of data collection were identified. Age, type, grade, cate-
gory of cancer, molecular markers including ER, PR, HER2, imag-
ing size, nodal status, chemotherapy regimen and pathological
response were recorded. Chi squared and Fisher Exact test were
used for statistical analysis.
Results: Eleven patients (19.6%) undergoing neo-adjuvant che-
motherapy had a complete pathological response and 6 patients
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